These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

138 related items for PubMed ID: 1833823

  • 1. Endocrine therapy for advanced stage D prostate cancer.
    Taylor TK.
    Urol Nurs; 1991 Sep; 11(3):22-6. PubMed ID: 1833823
    [No Abstract] [Full Text] [Related]

  • 2. [What is safe in the therapy of advanced prostatic cancer?].
    Gropp C, Burk K.
    Internist (Berl); 1985 Dec; 26(12):765-70. PubMed ID: 3936819
    [No Abstract] [Full Text] [Related]

  • 3. Maximal androgen blockade in prostatic cancer.
    Denis L.
    Scand J Urol Nephrol Suppl; 1991 Dec; 138():137-44. PubMed ID: 1838427
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [Zoladex in prostatic carcinoma].
    Di Silverio F, Serio M.
    Drugs Exp Clin Res; 1990 Dec; 16 Suppl():19-29. PubMed ID: 2150501
    [No Abstract] [Full Text] [Related]

  • 7. Long term therapy with a depot LHRH analogue (Zoladex) in patients with advanced prostatic cancer.
    Denis L, Keuppens F, Mahler C, Debruyne FM, Weil EH, Lunglmayr G, Newling D, Robinson MR, Richards B, Smith PH.
    Prog Clin Biol Res; 1987 Dec; 243A():221-7. PubMed ID: 2958852
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Re: Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma. A. V. Kaisary et al. Br. J. Urol., 67, 502-508, 1991.
    Bunce C.
    Br J Urol; 1992 Apr; 69(4):441-2. PubMed ID: 1533812
    [No Abstract] [Full Text] [Related]

  • 12. Recent developments in endocrine treatment of prostate cancer.
    Vogelzang NJ, Kennealey GT.
    Cancer; 1992 Aug 15; 70(4 Suppl):966-76. PubMed ID: 1386283
    [Abstract] [Full Text] [Related]

  • 13. The change in the dihydrotestosterone level in the prostate before and after androgen deprivation therapy in connection with prostate cancer aggressiveness using the Gleason score.
    Nishiyama T, Ikarashi T, Hashimoto Y, Wako K, Takahashi K.
    J Urol; 2007 Oct 15; 178(4 Pt 1):1282-8; discussion 1288-9. PubMed ID: 17698092
    [Abstract] [Full Text] [Related]

  • 14. [Principles for the conservative drug therapy treatment of prostate cancer].
    Hofmann W.
    Z Urol Nephrol; 1981 Sep 15; 74(9):697-704. PubMed ID: 7314992
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Evaluation of total versus partial androgen blockade in the treatment of advanced prostatic cancer.
    Schulze H, Kaldenhoff H, Senge T.
    Urol Int; 1988 Sep 15; 43(4):193-7. PubMed ID: 2973169
    [Abstract] [Full Text] [Related]

  • 17. The value of reversible androgen suppression as a diagnostic test.
    Newling DW.
    Prog Clin Biol Res; 1987 Sep 15; 243A():261-5. PubMed ID: 2958858
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Endocrine treatment of prostate cancer.
    Tammela T.
    J Steroid Biochem Mol Biol; 2004 Nov 15; 92(4):287-95. PubMed ID: 15663992
    [Abstract] [Full Text] [Related]

  • 20. Drug therapy of prostatic cancer.
    Huben RP, Perrapato SD.
    Drugs Aging; 1991 Nov 15; 1(5):353-63. PubMed ID: 1838950
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.